tiprankstipranks
Trending News
More News >
Ramm Pharma (TSE:RAMM)
:RAMM
Canadian Market
Advertisement

Ramm Pharma (RAMM) AI Stock Analysis

Compare
1 Followers

Top Page

TSE:RAMM

Ramm Pharma

(RAMM)

Rating:40Underperform
Price Target:
C$0.00
▼(-100.00%Downside)
The overall stock score of 40 reflects the significant financial challenges faced by Ramm Pharma, including operational losses and cash flow issues. The technical analysis provides mixed signals, with a general bearish trend. Valuation metrics further suggest a lack of investor appeal due to negative profitability and no dividends. The absence of earnings call and corporate events data limits additional insights.

Ramm Pharma (RAMM) vs. iShares MSCI Canada ETF (EWC)

Ramm Pharma Business Overview & Revenue Model

Company DescriptionRamm Pharma (RAMM) is a pharmaceutical company that specializes in the development and commercialization of cannabinoid-based products. The company operates in the medical, pharmaceutical, and wellness sectors, offering a range of products that include prescription medications, over-the-counter treatments, and wellness supplements. Ramm Pharma focuses on leveraging its expertise in cannabinoid research to provide innovative solutions for various health conditions.
How the Company Makes MoneyRamm Pharma makes money primarily through the sale of its cannabinoid-based pharmaceutical and wellness products. The company's revenue streams include direct sales to healthcare providers, pharmacies, and distributors, as well as partnerships with other pharmaceutical companies for co-development and distribution agreements. Additionally, Ramm Pharma may generate income from licensing its proprietary formulations and technologies to other entities. Strategic partnerships and collaborations with research institutions and healthcare organizations also contribute to the company's earnings by expanding its market reach and product offerings.

Ramm Pharma Financial Statement Overview

Summary
Ramm Pharma is facing significant financial difficulties. The company struggles with operational losses and cash flow constraints, as evidenced by a negative net income of -$13.7M and negative free cash flow. Despite a solid equity position with low debt, the ongoing losses and liquidity challenges present substantial risks.
Income Statement
35
Negative
Ramm Pharma's income statement reveals significant challenges. The TTM data shows a negative net income of -$13.7M, indicating substantial losses. The gross profit margin is approximately 36.8%, which is decent but overshadowed by negative EBIT and EBITDA margins, suggesting operational inefficiencies. Revenue has decreased from the previous period, indicating a contraction in sales growth. Overall, the company struggles with maintaining profitability and growth.
Balance Sheet
50
Neutral
The balance sheet shows a relatively strong equity position with stockholders' equity making up over 81.9% of total assets. The debt-to-equity ratio is very low at 0.0034, indicating limited reliance on debt. However, the company faces liquidity challenges with a shrinking cash position. While the low leverage is a strength, the declining asset base and equity value pose risks.
Cash Flow
30
Negative
Ramm Pharma's cash flow statement highlights cash management issues. The company has a negative free cash flow of -$2.5M in the TTM, showing a high cash burn rate. The operating cash flow to net income ratio is negative, reflecting poor cash generation from operations. Overall, the company faces substantial cash flow challenges, impacting its ability to invest and sustain operations.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.34M5.07M3.90M4.12M5.44M
Gross Profit1.76M381.82K530.50K-7.64K1.28M
EBITDA-15.23M-6.30M-19.91M-6.36M-6.91M
Net Income-16.50M-7.72M-20.96M-7.11M-7.43M
Balance Sheet
Total Assets16.75M32.30M39.31M59.71M37.17M
Cash, Cash Equivalents and Short-Term Investments814.04K5.12M9.77M17.16M28.01M
Total Debt188.31K405.14K683.70K32.16K100.43K
Total Liabilities3.11M2.84M3.72M3.32M1.34M
Stockholders Equity13.63M29.46M35.59M56.39M35.84M
Cash Flow
Free Cash Flow-4.05M-4.45M-6.08M-4.25M-4.80M
Operating Cash Flow-4.00M-4.34M-5.91M-3.82M-2.91M
Investing Cash Flow-47.43K126.58K-1.15M-6.83M-1.56M
Financing Cash Flow-258.23K-409.97K-353.77K-190.33K-2.91M

Ramm Pharma Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.01
Price Trends
50DMA
0.01
Negative
100DMA
0.01
Negative
200DMA
0.02
Negative
Market Momentum
MACD
<0.01
Negative
RSI
47.76
Neutral
STOCH
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RAMM, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 47.76 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RAMM.

Ramm Pharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
46
Neutral
C$205.89M-3.31-23.14%2.77%20.79%-0.36%
40
Underperform
C$1.19M-70.13%-10.69%-53.89%
39
Underperform
$2.11M62.01%35.35%31.85%
29
Underperform
C$1.62M-405.57%-2291.11%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:RAMM
Ramm Pharma
0.01
-0.01
-50.00%
TSE:OVAT
Ovation Science
0.05
<0.01
28.57%
TSE:PHRX
Pharmadrug
0.01
0.00
0.00%

Ramm Pharma Corporate Events

M&A TransactionsBusiness Operations and Strategy
RAMM Pharma Explores Sale of Italian Subsidiary Canapar
Neutral
Jan 21, 2025

RAMM Pharma Corp. is considering the sale of its subsidiary, Canapar Corp., and its facility in Italy as part of its strategy to streamline operations and focus on core businesses. This potential sale is aimed at enhancing shareholder value and ensuring long-term company sustainability. However, there is no guarantee that a sale will occur, and updates will be provided as the process progresses.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 26, 2025